With a market capitalization (market cap) of $2.04B — a measure of how much the company is worth — Aurinia Pharmaceuticals Inc. ranks #2,026 among the 2,510 companies tracked, and 247th in Healthcare as of October 3, 2026. Shares trade at $15.83, down 0.75% on the day.
of 2,510 tracked
Market-cap change uses historical capitalization records. Share-price returns are a different series — they can diverge when the share count changes. Those returns are not a CAGR until you pick a start value, an ending value, and years. CAGR calculator. Market cap vs. stock price.
Year-end values and the chart both come from historical market-cap records, not from applying today's share count to past prices. Latest historical observation October 2, 2026. Ranking headline cap is the snapshot figure as of October 3, 2026.
| Year | As of | Market cap | Annual change | Year-end close |
|---|---|---|---|---|
| 2026 | Oct 2, 2026 | $2.06B | -2.47% | $15.83 |
| 2025 | Dec 31, 2025 | $2.11B | +69.25% | $15.95 |
| 2024 | Dec 31, 2024 | $1.25B | -3.39% | $8.98 |
| 2023 | Dec 29, 2023 | $1.29B | +110.09% | $8.99 |
| 2022 |
Ranking figure $2.04B as of October 3, 2026.
Aurinia Pharmaceuticals Inc.'s ranking market cap is the provider-reported capitalization on the same snapshot as the rest of this site, with a share price of $15.83 as of October 2, 2026. Charts and the year-end table use a separate historical market-cap series, last observed at $2.06B on October 2, 2026. See how the ranking works.
Live shares outstanding are not on the quote used for price, so this page does not invent a current share count. Shares outstanding vs. float.
The latest annual report (FY 2025) used a weighted-average 134,367,000 shares. That figure is an average for the year, not the live count in the market-cap formula.
Book equity: assets minus liabilities on the latest annual report.
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Not in this snapshot
FY 2025 net worth
Largest U.S.-listed names in the same FMP sector — not a hand-picked competitor set.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #14 | Eli Lilly and Company LLY | $1.08T | -0.61% |
| #21 | Johnson & Johnson JNJ | $617.01B | -1.02% |
| #24 |
Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis.
Summary from the company profile (Financial Modeling Prep). Principal financial figures above are for FY 2025.
Visit websiteAs of October 3, 2026, Aurinia Pharmaceuticals Inc. (AUPH) is worth $2.04B — that is its market capitalization, the total value of its outstanding shares on MarketCapLens.
A company’s net worth is its shareholders’ equity: assets minus liabilities on the balance sheet. That is book equity, not market cap. For FY 2025, Aurinia Pharmaceuticals Inc.’s book equity is about $581.33M. Market cap is the market value of the outstanding shares. As of October 3, 2026, its market cap is $2.04B. Book equity is an accounting remainder; market cap is a trading value. Neither is a person’s net worth.
Aurinia Pharmaceuticals Inc. ranks #2,026 among the 2,510 companies tracked on MarketCapLens. In Healthcare it ranks #247 of 350.
Fundamentals are annual. Figures labeled with their fiscal year. Live ratios use the current price against those annual earnings.
| Dec 30, 2022 |
| $614.6M |
| -81.03% |
| $4.32 |
| 2021 | Dec 31, 2021 | $3.24B | — | $22.87 |
|---|
Last observation of each calendar year from historical market-cap records. The current year is through the latest date, not a completed year-end. Share-price close is the matching session for context — we do not rebuild cap from today's share count.
Not in this snapshot
FY 2025
| $464.35B |
| +1.11% |
| #36 | Merck & Co., Inc. MRK | $356.4B | +0.34% |
| #38 | UnitedHealth Group Incorporated UNH | $337.74B | +1.83% |
| #52 | Novartis AG NVS | $268B | -0.04% |
Companies immediately above and below in the overall ranking. They may be in a different sector.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #2023 | Asana, Inc. ASAN | $2.05B | -3.47% |
| #2024 | nCino, Inc. NCNO | $2.05B | -3.46% |
| #2025 | The Gorman-Rupp Company GRC | $2.04B | +2.84% |
| #2027 | Ziff Davis, Inc. ZD | $2.03B | +1.43% |
| #2028 | NGL Energy Partners LP NGL | $2.03B | +4.42% |
| #2029 | The Bancorp, Inc. TBBK | $2.03B | -0.27% |
Aurinia Pharmaceuticals Inc.’s ranking market cap of $2.04B comes from the same snapshot as the rest of this site, as of October 3, 2026. It is not share price multiplied by the FY 2025 weighted-average share count of 134,367,000. The historical market-cap series last observed $2.06B on October 2, 2026.
Over the past year, Aurinia Pharmaceuticals Inc.’s market cap is up 36.10%, using historical market-cap records rather than today’s share count applied to past prices.
Aurinia Pharmaceuticals Inc. (AUPH) shares trade at $15.83, down 0.75% on the day, as of October 3, 2026.
Aurinia Pharmaceuticals Inc. trades at a live price-to-earnings (P/E) ratio of 7.4, using the latest share price divided by the latest annual earnings per share. That is not the same as a fiscal-year reported P/E.